The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.
A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.
The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
Researchers are revealing the complexity of the microbial community living on the body—and paving the way for new bacteria-targeting treatments for acne and other dermatological conditions.